2. Cancer
  3. Cancer Metabolism and Metastasis

Cancer Metabolism and Metastasis

Metabolic abnormalities are a major feature of cancer, such as increased substance anabolic pathways and aerobic glycolysis. Cancer metabolism shows flexibility and plasticity, which are crucial for the survival and growth of cancer cells. Cancer metastasis is completed in five steps i.e. invasion, dissemination, circulating tumor cells, colonization, and secondary tumor formation. Recently, metabolic adaptation mechanism of cancer metastasis has been proposed to reveal the extensive relationship between cancer metabolism and cancer metastasis. Metastasizing cancer cells selectively and dynamically adapt their metabolism during the complex multistep cascade.

Many nutrients can promote metabolite plasticity during metastasis. For example, lactic acid and pyruvate are the nutrients that cells can directly absorb from the environment; many cancer cells take up glutamine, which contributes to non-essential amino acid as well as nucleotide synthesis through nitrogen or carbon metabolism. Inhibiting the function of key enzymes in metabolic pathways can in turn inhibit the proliferation of cancer cells. For example, lactate dehydrogenase A or B (LDH-A or -B) knockdown can inhibit breast cancer cell motility in vitro. Oncogenic signaling pathways, such as Myc, phosphoinositide 3-kinase (PI3K)/AKT pathway, MAPK/ERK pathway, LKB1/AMPK pathway and Hippo pathways, mediate metabolic gene expression and increase metabolic enzyme activities.

Cancer Metabolism and Metastasis 관련 제품 (50745):

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-RI02409
    hsa-miR-762 inhibitor
    hsa-miR-762 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-762 inhibitor
  • HY-N2037AS
    Higenamine-d4 hydrochloride 2249814-84-2
    Higenamine-d4 (Norcoclaurine-d4; Demethyl-Coclaurine-d4) hydrochloride is deuterium-labeled Higenamine (hydrochloride) (HY-N2037A).
    Higenamine-d<sub>4</sub> hydrochloride
  • HY-R01760
    hsa-miR-5681b mimic
    hsa-miR-5681b mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-5681b mimic
  • HY-RI02753A
    mmu-miR-193a-5p antagomir
    mmu-miR-193a-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    mmu-miR-193a-5p antagomir
  • HY-114923
    SU-11752 688036-19-3
    SU-11752 is an inhibitor for DNA-dependent protein kinase (DNA-PK) with an IC50 of 0.13 μM. SU-11752 inhibits PI3K p110γ kinase with IC50 of 1.1 μM. SU-11752 binds competitively for ATP-site in DNA-PK, results in inhibition of intracellular DNA double-strand break repair and increases the sensitivity of cells to radiotherapy.
    SU-11752
  • HY-RI04472
    rno-miR-450b-5p inhibitor
    rno-miR-450b-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    rno-miR-450b-5p inhibitor
  • HY-R02248A
    hsa-miR-6842-3p agomir
    hsa-miR-6842-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-6842-3p agomir
  • HY-P11494
    AWWNTEW
    AWWNTEW (CP29) is a FOXM1-DBD peptide ligand with cytotoxicity to cancer cells. AWWNTEW has a strong affinity and binds to the FOXM1 protein. AWWNTEW is a component of FPP29 (HY-P11228). X
    AWWNTEW
  • HY-154264
    5’-O-DMTr-N6-ethyl-2’-deoxyadenosine 3’-CED phosphoramidite
    5’-O-DMTr-N6-ethyl-2’-deoxyadenosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
    5’-O-DMTr-N6-ethyl-2’-deoxyadenosine 3’-CED phosphoramidite
  • HY-154477
    2-Amino-6-chloro-9-(3-deoxy-beta-D-ribofuanosyl)-9H-purine 1055035-48-7
    2-Amino-6-chloro-9-(3-deoxy-beta-D-ribofuanosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
    2-Amino-6-chloro-9-(3-deoxy-beta-D-ribofuanosyl)-9H-purine
  • HY-W080687
    1,3-Diaminotetrafluorobenzene 1198-63-6
    1,3-Diaminotetrafluorobenzene (2,4,5,6-Tetrafluorobenzene-1,3-diamine) (Compound 48) is a carcinogenic aniline with carcinogenic activity.
    1,3-Diaminotetrafluorobenzene
  • HY-19612
    DDP-38003 1831167-97-5
    DDP-38003 (Compound 15) is an orally active KDM1A/LSD1 inhibitor with an IC50 value of 84 nM. DDP-38003 exhibits anticancer activity against promyelocytic leukemia.
    DDP-38003
  • HY-17437C
    (Rac)-Mefloquine 49752-90-1
    (Rac)-Mefloquine ((Rac)-Mefloquin) is an orally active NF-κB inhibitor. (Rac)-Mefloquine inhibits the NF-κB and IKK signaling pathways, suppresses NF-κB-Luc luciferase activity, blocks the activation of p65 and IκBα, and reduces the expression of downstream target genes of NF-κB. (Rac)-Mefloquine activates apoptosis-related factors and induces apoptosis in tumor cells. (Rac)-Mefloquine functions as a tumor cell inhibitor. (Rac)-Mefloquine can be used for the research of colorectal cancer.
    (Rac)-Mefloquine
  • HY-N1833
    3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone 1334309-44-2 99.12%
    3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone displays cytotoxicity of 1.32, 3.92 and 5.22 μm against the human cervical carcinoma HeLa, human breast carcinoma MCF-7, and human hepatocarcinoma Hep3B cells.
    3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone
  • HY-176147
    Apoptosis inducer 38
    Apoptosis inducer 38 (compound CA7) is a potent Apoptosis inducer. Apoptosis inducer 38 inhibits MDA-MB-231 activity with an IC50 of 0.45 μM.
    Apoptosis inducer 38
  • HY-179344
    Benzazepinoquinoline-spermine 2250121-20-9
    Benzazepinoquinoline-spermine (Compound PA-3) is an efficient pre-miR-372 complexing agent, and it can specifically inhibit its processing mediated by Dicer. Its IC₅₀ value is 0.58 μM. Benzazepinoquinoline-spermine has a strong affinity for pre-miR-372, with a KD value of 0.11 μM. Benzazepinoquinoline-spermine also shows high activity against pre-miR-373 (IC₅₀ = 0.29 μM), but significantly reduced inhibitory activity against pre-miR-17, pre-miR-21, and pre-miR-155 (IC₅₀ being 0.84 μM, 1.43 μM, and 1.07 μM respectively). Benzazepinoquinoline-spermine can be used for cancer research.
    Benzazepinoquinoline-spermine
  • HY-184250
    FGFR-IN-28 2634677-16-8
    FGFR-IN-28 is a FGFR inhibitor with inhibitory activity against multiple subtypes of the FGFR family, with an IC50 of 4.4 nM against FGFR4. FGFR-IN-28 inhibits kinase activity and phosphorylation processes, and blocks the downstream MAPK and AKT signaling pathways. FGFR-IN-28 induces cellular DNA damage, cell cycle arrest, apoptosis and ferroptosis, and reduces the adhesion, invasion and metastasis abilities of cancer cells. FGFR-IN-28 exhibits anti-tumor activity in in vitro experiments on colon cancer cells, and inhibits tumor growth in colon cancer xenograft models. FGFR-IN-28 can be used in colon cancer-related research.
    FGFR-IN-28
  • HY-P3214
    Myosin light chain kinase fragment 11-19 amide 119386-39-9
    Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin light chain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca2+ entry. Myosin light chain kinase fragment 11-19 amide can be used in the research of human cervical cancer.
    Myosin light chain kinase fragment 11-19 amide
  • HY-163535
    J208 2116468-11-0
    J208 is a dual inhibitor for histone deacetylase (HDAC) and DNA methyltransferase (DNMT). J208 inhibits proliferation of cancer cells, as well as the migration/invasion of triple-negative breast cancer (TNBC) cells. J208 induces apoptosis, arrests the cell cycle at G0/G1 phase. J2008 activates the innate immune signalling pathway in TNBC, by inducing the expression of endogenous retroviruses (ERVs).
    J208
  • HY-RI01851
    hsa-miR-6077 inhibitor
    hsa-miR-6077 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-6077 inhibitor